东诚药业：225Ac-LNC1011注射液正进行临床入组前的准备工作

Core Viewpoint - The company is preparing for clinical trials of its 225Ac-LNC1011 injection, with approvals from both the U.S. FDA and China's NMPA expected by August and September 2025 respectively [2]. Group 1: Clinical Trial Progress - The company has received approval notifications for the clinical trial of 225Ac-LNC1011 injection from the U.S. FDA and China's NMPA, scheduled for August 22, 2025, and September 22, 2025 [2]. - The company is currently preparing for patient enrollment prior to the clinical trials [2]. - The company commits to actively advancing the research and development project in accordance with relevant national regulations and will fulfill information disclosure obligations regarding subsequent project progress [2].